Lataa...
Repurposing CRISPR/Cas9 for in situ functional assays
RNAi combined with next-generation sequencing has proven to be a powerful and cost-effective genetic screening platform in mammalian cells. Still, this technology has its limitations and is incompatible with in situ mutagenesis screens on a genome-wide scale. Using p53 as a proof-of-principle target...
Tallennettuna:
| Päätekijät: | , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Cold Spring Harbor Laboratory Press
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3861673/ https://ncbi.nlm.nih.gov/pubmed/24298059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.227132.113 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|